Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Impact of 200 PTEN variants on canonical and non-conical signalling pathways

EF 2022-23

Résumé
Phosphatase and Tensin Homolog deleted on Chromosome 10 (PTEN) regulates cell metabolism, growth, survival, and proliferation. PTEN has been linked in the development autism spectrum disorder (ASD), multiple cancers and non-cancerous brain tumors called PTEN hamartoma syndrome (PHTS). In the traditional model, PTEN regulates abnormal growth through the suppression of PI3K/Akt/mTOR activity. However, identification of new functions and interacting partners of PTEN suggest a more complicated story. The most common PTEN disease-associated mutations are single amino acid substitutions, with unknown impacts on protein function. Understanding how these mutations impact the various functions of PTEN is important in the development of new therapeutic targets and treatment options. Here, we propose to test the impact of 200 disease-associated PTEN mutation on Akt and non-traditional signaling pathways using Cytometry by Time of Flight (CyTOF). We will first validate CyTOF as a new tool for studying signaling pathways in non-immune type cells, as it has many advantages over other technologies. CyTOF allows us to test up to 40 markers across various PTEN associated pathways in the same cells. The testing of 200 PTEN disease-associated variants will allow us to gain mutation-specific impacts on different signaling pathways. From our results, we expect to identify downstream signaling proteins where the impacts of PTEN dysfunctions coverage, and potentially illuminating how mutations in the same protein give rise to different diseases. A goal of this proposal is to target these downstream proteins with therapeutics to compensate for PTEN mutation-induced imbalance of signaling pathways in order to improve treatment options for individuals affected by ASD, cancer and PHTS.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486281
Name
Glufka Corbin
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Impact of 200 PTEN variants on canonical and non-conical signalling pathways
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Tumors; Cell Signaling; Cytometry By Time Of Flight; Mutations; Protein Interaction; Single Cell; Therapeutics
Abstract
Phosphatase and Tensin Homolog deleted on Chromosome 10 (PTEN) regulates cell metabolism, growth, survival, and proliferation. PTEN has been linked in the development autism spectrum disorder (ASD), multiple cancers and non-cancerous brain tumors called PTEN hamartoma syndrome (PHTS). In the traditional model, PTEN regulates abnormal growth through the suppression of PI3K/Akt/mTOR activity. However, identification of new functions and interacting partners of PTEN suggest a more complicated story. The most common PTEN disease-associated mutations are single amino acid substitutions, with unknown impacts on protein function. Understanding how these mutations impact the various functions of PTEN is important in the development of new therapeutic targets and treatment options. Here, we propose to test the impact of 200 disease-associated PTEN mutation on Akt and non-traditional signaling pathways using Cytometry by Time of Flight (CyTOF). We will first validate CyTOF as a new tool for studying signaling pathways in non-immune type cells, as it has many advantages over other technologies. CyTOF allows us to test up to 40 markers across various PTEN associated pathways in the same cells. The testing of 200 PTEN disease-associated variants will allow us to gain mutation-specific impacts on different signaling pathways. From our results, we expect to identify downstream signaling proteins where the impacts of PTEN dysfunctions coverage, and potentially illuminating how mutations in the same protein give rise to different diseases. A goal of this proposal is to target these downstream proteins with therapeutics to compensate for PTEN mutation-induced imbalance of signaling pathways in order to improve treatment options for individuals affected by ASD, cancer and PHTS.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Glufka, Corbin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~